RxSight (NASDAQ:RXST – Get Rating) will post its quarterly earnings results after the market closes on Monday, August 8th. Analysts expect RxSight to post earnings of ($0.68) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.
RxSight (NASDAQ:RXST – Get Rating) last posted its earnings results on Thursday, May 5th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.02. The company had revenue of $8.94 million during the quarter, compared to analyst estimates of $7.73 million. RxSight had a negative return on equity of 251.55% and a negative net margin of 212.04%. On average, analysts expect RxSight to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
RxSight Stock Up 4.2 %
NASDAQ:RXST opened at $15.70 on Friday. RxSight has a 52 week low of $8.80 and a 52 week high of $16.99. The company has a current ratio of 15.12, a quick ratio of 14.32 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $431.83 million and a PE ratio of -2.89. The stock has a 50 day moving average of $14.49 and a 200-day moving average of $13.11.
Institutional Investors Weigh In On RxSight
Wall Street Analysts Forecast Growth
Separately, Needham & Company LLC started coverage on RxSight in a report on Friday, April 8th. They set a “buy” rating and a $18.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $19.83.
RxSight Company Profile
RxSight, Inc, a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
- Get a free copy of the StockNews.com research report on RxSight (RXST)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.